A medical device comprising: a balloon; and a coating on at least a portion of the balloon, wherein the coating is provided by depositing encapsulated particles of a pharmaceutical agent, wherein each particle of the pharmaceutical agent is at least partially encapsulated in a first polymer, wherein a binding agent is deposited on the exterior surface of said encapsulated particles, and wherein the weight ratio between the binding agent and the first polymer is from 1:99 to 25:75, and wherein a second polymer, which is poly(lactide-co-glycolide) is deposited on the medical device following the deposition of said encapsulated particles; and wherein the encapsulated particles of the pharmaceutical agent are deposited on the balloon using an eSTAT coating process, wherein a first polymer is selected from the group consisting of polylactides (PLA), polyglycolides (PGA), polylactide-co-glycolides (PLGA), polyanhydrides, polyorthoesters, poly(N-(2- hydroxypropyl) methacrylamide), poly(l-aspartamide), including the derivatives DLPLA - poly(dl-lactide); LPLA - poly(l-lactide); PDO-poly(dioxanone); PGA-TMC - poly(glycolide-co-trimethylene carbonate); PGA-LPLA - poly(l-lactide-co-glycolide); PGA-DLPLA - poly(dl-lactide-co-glycolide); LPLA-DLPLA - poly(l-lactide-co-dl-lactide); and PDO-PGA-TMC - poly(glycolide-co-trimethylene carbonate-co-dioxanone), and combinations thereof, and the binding agent is selected from the group consisting of octenidine dihydrochloride; an alkyltrimethylammonium salt; cetylpyridinium chloride (CPC); polyethoxylated tallow amine (POEA); benzalkonium chloride (BAC); benzethonium chloride (BZT); 5-bromo-5-nitro-1,3-dioxane; dimethyldioctadecylammonium chloride; dioctadecyldimethylammonium bromide (DODAB); polyarginine, polyarginine 9-L-pArg, poly-L-lysine, diethylaminoethyl cellulose-Dextran (DEAE-Dextran), didodecyldimethylammonium bromide (DMAB), polyethyleneimine (PEI), tetradodecylammonium bromide (TAB), and dimethylditetradecylammonium bromide (DMTAB), poly histidine, ethylhexadecyldimethylammonium bromide, tetradodecylammonium bromide, dimethylditetradecyl ammonium bromide, tetrabutylammonium iodide, DEAE-Dextran hydrochloride, and hexadimethrine bromide. a balloon; and a coating on at least a portion of the balloon, wherein the coating is provided by depositing encapsulated particles of a pharmaceutical agent, wherein each particle of the pharmaceutical agent is at least partially encapsulated in a first polymer, wherein a binding agent is deposited on the exterior surface of said encapsulated particles, and wherein the weight ratio between the binding agent and the first polymer is from 1:99 to 25:75, and wherein a second polymer, which is poly(lactide-co-glycolide) is deposited on the medical device following the deposition of said encapsulated particles; and wherein the encapsulated particles of the pharmaceutical agent are deposited on the balloon using an eSTAT coating process, wherein the binding agent is selected from the group consisting of octenidine dihydrochloride; an alkyltrimethylammonium salt; cetylpyridinium chloride (CPC); polyethoxylated tallow amine (POEA); benzalkonium chloride (BAC); benzethonium chloride (BZT); 5-bromo-5-nitro-1,3-dioxane; dimethyldioctadecylammonium chloride; dioctadecyldimethylammonium bromide (DODAB); polyarginine, polyarginine 9-L-pArg, poly-L-lysine, diethylaminoethyl cellulose-Dextran (DEAE-Dextran), didodecyldimethylammonium bromide (DMAB), polyethyleneimine (PEI), tetradodecylammonium bromide (TAB), and dimethylditetradecylammonium bromide (DMTAB), poly histidine, ethylhexadecyldimethylammonium bromide, tetradodecylammonium bromide, dimethylditetradecyl ammonium bromide, tetrabutylammonium iodide, DEAE-Dextran hydrochloride, and hexadimethrine bromide. <EOS>